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S U M M A R Y  Serum concen tra tions  of IgG may influence Fc 
receptor-m ediated clearance of im m une complexes. For 
instance, when 12 31-labeled aggregates of hum an  IgG ( l 23I- 
AlgG). used as a model for soluble im m une complexes, are 
adm inistered  to patients with systemic lupus ery them atosus  
(SLE), there is an inverse correlation between the serum 
concen tra tions  of IiiG and the clearance and volume of 
d is tr ibu tion  in steady state (Vss) of 1 23I-AIgG. T o  answer the 
question w hether IgG has a direct effect on the clearance of 
im m une complexes, we m easured the elim ination of 123 I-AIgG 
in eight patients with hypogam m aglobulinem ia, before and 
after substitu tion  with in travenous gam m aglobulin  (IVIG). As
expected, raising IgG concentra tions in these patients (by 6 g/1) 
caused a significant decrease of the Vss of 123 I-AIeG. However, 
clearance of 123 I-AIgG remained unchanged by IVIG. Thus, 
the results of this study offer no experimental evidence that 
raising concen tra tions of IgG influences the clearance of soluble 
im m une complexes.
K ey words: Im m unoglobulin  G, aggregates of im m unoglobulin  
G, Fc receptor function, im m une complex endocytosis, systemic 
lupus ery them atosus
I n t r o d u c t i o n
I m p a i r m e n t  of Fc receptor-mediated clearance may play 
an important role in immune complex disease, as for 
instance systemic lupus erythematosus (SLE) (1). Fc 
receptor-dependent clearance is thought to be influenced 
by the plasma concentration of monomeric IgG. This is 
based on the observation that the elimination of erythro­
cytes coated with IgG (E -IgG ) decreases with inceasing 
plasma concentrations of IgG (2). Furthermore, admin-
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istration of intravenous immunoglobulin G (IVIG) re­
duces the clearance of E -Ig G  (3). E -Ig G  is a particle-like 
probe and clearance of E -Ig G  is largely a measure of 
splenic Fc receptor function (4). The effect of the serum 
concentration of IgG on hepatic Fc receptor-mediated 
clearance is unknown.
Hepatic Fc receptor function can be assessed by 
evaluating the dissappearance of aggregates of IgG from 
the circulation (5, 6). These aggregates have biologic 
activities similar to soluble immune complexes: they 
activate complement, subsequently bind to C3b receptors 
(CR1) on erythrocytes, and are cleared by hepatic Fc 
receptor-mediated mechanisms. Using soluble 123I- 
labeled aggregates of human IgG ( 123I-AIgG) as a model
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for immune complexes in patients with SLE, we found 
that clearance of 123I-AIgG was strongly and inversely 
correlated with plasma IgG concentration (7). From this 
study the question rose whether plasma IgG interferes 
directly with the clearance of soluble immune complexes, 
similarly to its effect on the elimination of E -Ig G  (3). To  
answer this question, we measured the clearance of l 23I- 
AlgG in patients with hypogammaglobulinemia, before 
and after administration of IVIG.
M a t e r i a l s  a n d  M f t h o d s
Patients
Eight patients with hypogammaglobulinemia (7M, 1 F, 
aged 2 0 -3 4  years) participated in the study. Diagnoses  
were X-linked agammaglobulinemia or late onset hypo­
gammaglobulinemia. The patients were on regular sub­
stitution therapy with intravenous or subcutaneous IgG, 
and all were free of infection at the time of study. They 
were studied before and after substitution with IVIG 
(Central Laboratory of the Blood Transfusion Service, 
Amsterdam, The Netherlands). IVIG was given twice: 
18 g were given immediately following the first clearance 
experiment, and this was repeated on the day before the 
second clearance experiment. The time between the two 
clearance studies was seven days.
To prevent thyroid uptake of 123I, all subjects were 
given N al orally 12 and 2 hours prior to the experiments. 
Blood pressure and pulse rale were monitored during the 
experiment.
The study protocol was approved by the local Ethical 
Committee. All patients gave informed consent, before 
participating in the study.
Preparation o f  Human l2 i I-AIcjG
Aggregates of human IgG were prepared as previously 
described and stored at — 70° (6). On the day of the study 
1 ml of aggregates was thawed and mixed with 15M Bq  
(1 Megabecquerel =  0 027 mCi) N a l23I in a sterile lube, 
coated with Iodogen (8). After 15min the radio-labeled 
solution was passed over a 0-22 |im filter. The filter was 
flushed with saline and an aliquot of the final solution  
was given to each subject. The amount of radioactivity 
administered was 01 M Bq/kg body weight, of which 50% 
was associated with aggregates of IgG (as assessed by 
PEG precipitation, see below).
Clearance o f X22>l -AIgG
The clearance of 123I-AIgG was assessed as described 
previously (7). The subjects received approximately 1 mg 
of 123I-AIgG intravenously over 3 0 sec. From the 
opposite forearm serial blood samples were collected into
chilled tubes, containing heparin. The samples were kept 
on icc until processed. 150min after injection. Radio­
activity was counted in 0-5 ml samples of whole blood  
and plasma. Aggregate-bound radioactivity was assessed 
by treating plasma samples with 3% (final concentration) 
polyethyleneglycol (PEG) for 30m in at 0°, followed by 
centrifugation and counting of the precipitate. At this 
PEG concentration at least 95% of IgG aggregates and 
less than 5% of monomeric IgG is precipitated (6). 
Erythrocyte-bound radioactivity was measured after 
washing 0-5 ml samples of whole blood twice with 2 ml of 
PBS at 0°. Radioactivity was counted in a Minaxi Auto- 
Gamma 5530 Counter (Packard, Downers Grove, IL, 
USA).
The amount of PEG-precipitable radioactivity in 
plasma per ml of whole blood was calculated as:
(whole blood —E) x (PEG/plasma) (in cpm/ml).
In this formula E stands for erythrocyte-bound cpm; 
PEG for PEG-precipitable cpm. The total amount of 
aggregate-bound radioactivity per ml of whole blood was 
then calculated by adding the PEG-precipitable cpm/ml, 
obtained with this formula, to the erythrocyte-bound  
cpm per ml. This total amount of 123I-AIgG (PEG- 
precipitable cpm in plasma and erythrocyte-bound cpm) 
per ml of whole blood was subsequently used in all 
calculations.
Concentrations of serum IgG were measured by radial 
immunodiffusion. Anti-IgG antibodies were obtained by 
immunisation of rabbits with purified IgG and rendered 
gamma-chain specific by absorption with kappa and 
lambda light chains. As a standard human serum of a 
known IgG concentration was used.
As 123I-AIgG is heterogenous in size, disappearance of 
aggregates from the circulation was assessed in more 
detail by sucrose density gradient ultracentrifugation of 
plasma samples, as previously described (6).
Organ Uptake o f 123/-/I I ljG
Radioactivity over hepatic and splenic areas was 
registered continuously with a gamma camera (GCA 40 A, 
Toshiba, Tokyo, Japan) for 1 h after the injection, using 
regions of interest (7). Organ counts were corrected for 
background. Background counts were obtained from a 
standard area below the aortic bifurcation. Organ 
uptakes were calculated as (organ minus background)/ 
background ratio. Maximal uptake ratios and the time of 
maximal uptake were determined.
Pharmacokinetic Analysis and Statistics
Residual radioactivity-time curves of the total amount 
of aggregates per ml of blood (PEG-precipitable and
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E-bound, calculated according to the formula described 
above) were plotted. The disappearance curves were 
analyzed by non-linear regression analysis, according to 
standard pharmacokinetic methods (9), using the 
computer programme SIPHAR (Scimcd, Créteil, France). 
A biexponential model was used. The area under the 
curve (AUC) was calculated by trapezoidal rule, with 
extrapolation to infinity. Clearance was calculated as 
dose/A U C. Volume of distribution in steady state (Vss) 
was calculated as (dose x A U M Q /A U C 2, in which 
A U M C  is the area under the curve of the products of time 
and concentration. The dose of radioactivity entered in 
the calculations was the number of PEG-precipitable 
cpm administered. Clearance and Vss were normalized 
for body weight.
Group means were compared using Student's t-test for 
paired data. The disappearance curves before and after 
IVIG in the hypogammaglobulinémie patients were 
compared by applying the paired t-test at each time 
point, with correction for multiple testing. To compare 
the effect of IgG concentrations on the pharmacokinetics 
of 123I-AIgG in the hypogammaglobulinémie patients 
with the results obtained prevously in patients with SLE 
(7), data from this study were reanalyzed. In 22 patients 
with SLE significant correlations were present between 
levels of IgG (range 1 —25-4 g/1) and various pharmaco­
kinetic parameters of 123I-AIgG (clearance, Vss and first 
halflife). With these data regression analysis was per­
formed. The concentration of IgG was taken as the 
independent variable, and the pharmacokinetic par­
ameters (clearance, Vss, and halflifes) were taken as 
dependent variables. In the resulting regression 
equations, we substituted the values of the IgG con­
centrations obtained in the patients with hypogam m a­
globulinemia (4-6 and 11 0 g/1, see below) to predict the 
various pharmacokinetic parameters in the SLE patients 
for these given IgG concentrations. The predicted 
changes (percent increase or decrease from the value at 
the lower IgG concentration) in these parameters in the 
SLE patients were compared with the changes observed 
in the patients with hypogammaglobulinemia, before and 
after IVIG. Software used was SPSS. Values are given as 
mean +  SEM.
R e s u l t s
Administration of 123I-AIgG was well tolerated by the 
subjects. The disappearance curves could be described 
very well with the biexponential model. Correlation 
coefficients were >99%  for all curves. Thus, the 
disappearance curves had two components: the first 
having a short halflife (T |), the second having a longer 
halflife.
After administration of 2 x l 8 g  IVIG serum IgG 
concentrations rose from 4-6 +  1 • 1 to 11 -0 ±  1 *2 g/1 (Table). 
Analysis of the disappearance curves of 123I-AIgG  
showed that after treatment with IVIG residual 
aggregate-bound radioactivity was consistently higher at 
30m in and later time points after injection (Figure 1). 
When the amount of residual 123I-AIgG at various time- 
points after injection was compared before and after 
administration of IVIG, this difference reached statistical 
significance at 60 min (p <0-005).
Results of the pharmacokinetic analysis are shown in 
the Table and in Figure 2. The data shown in Figure 2 
(a, b, d) are those of seven (of eight) subjects. In one
Table 1 Pharm acok inetic  param eters  in patients with hypogam m aglobulinem ia, before and after 
the adm in is tra tion  of IVIG. The observed changes are com pared  with the expected changes in 
pharm acokinetics  in patients with SLE and similar concen tra tions  of IgG
Before
I VI G
After
I VI G
Observed 
change 
(hypog.)
Expected
change
(SLE)
Serum
IgG
Clearance
Vss
First T !  
Second T \
4-6+  1-1 
4 -5+  0-4 
7 8 6 ± 105 
5-47 +  0-5 
174+  18
1 1 -0 +  1-2 g/1 
4-6+  0-7 m l/m in /kg  
540 +  65 m l/kg 
5-37 ±0-63  min 
118 ±  14 min
139%*
90 *
3 T% t  
2%t 
32% t
139%*
21  % t  
24% f  
20%* 
3 % t
C hanges were expressed as the percentage of the value at the lower IgG concentra tion , which was 
taken to be 100%.
O bserved change: hypogam m aglobuliném ie  patients. Expected change: from d a ta  observed in SLE 
patients (7) and calculated by regression analysis (see Methods). * denotes an increase, t  a decrease.
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Figure 1. Radioactivity-time curves of 123I-AIgG (m e a n ±  
SEM), in eight patients with hypogam m aglobulinem ia  before 
and after (dotted line) adm in is tra tion  of IVIG. Asterisk: 
p <  0-005.
patient no statistically reliable fit was possible for the 
second phase. Therefore, the first halflife is the only 
pharmacokinetic parameter used in this patient.
Pharmacokinetic analysis revealed that clearance and 
first halllife of 123I-AIsG did not change after IVIGc
(Table, Figure 2A, 2C). However, Vss (Figure 2B) and 
second halllife (Figure 2D) decreased significantly 
(p =  0 0 4  and p =  0-049. respectively). The changes in 
pharmacokinetic parameters secondary to IVIG therapy 
were compared with the changes predicted from the data 
obtained in 22 patients with SLE (7). A similar increase of  
IgG concentration in the SLE patients should have 
resulted in a decrease in clearance and Vss, an increase in 
the first halflife and no change in the second halllife 
(Table).
Organ uptakes did not change significantly. Maximal 
liver uptake ratio was 2-7 ±0-2  before and 2-6 ±  1-0 after 
IVIG. Maximal splenic uptake ratio was 1-4±0-3 before 
and after IVIG. The time to reach maximal uptake in 
liver and spleen did not change after IVIG.
Sucrose density gradient ultracentrifugation experi­
ments were performed in several patients before and after 
IVIG. Results of a representative experiment are shown  
in Figure 3. There is a rapid disappearance of the larger 
sized aggregates in the first 3 0 min after injection. No  
changes were seen after treatment with IVIG.
Raising IgG concentrations did not change the clearance 
of 12M-AIgG in patients with hypogammaglobulinemia, 
although a 20(,o decrease was expected, based on the 
results obtained in a transversal study of SLE patients (7). 
In the SLE patients a highly significant inverse 
correlation was found between serum IgG on the one 
hand and clearance and Vss of 123I-AIgG on the other 
hand. First halflife was weakly and positively correlated 
with the concentration of IgG (7). Since administration of 
IVIG had no effect on clearance of 123I-AIgG. the 
decreased clearance of this probe observed in patients 
with SLE and elevated concentrations of serum IgG is 
probably not causally related to the high levels of IgG.
Of course, it cannot be excluded that continuous  
exposure of the M PS to a sustained high concentration of 
IgG, as present in the SLE patients, may affect clearance 
of immune complexes in a way different from the 
intermittently high levels of IgG in the hypogam m a­
globulinémie patients receiving IVIG. However, it seems 
likely that high IgG concentrations and decreased 
clearances of 123I-AIgG in this subgroup of SLE patients 
are independent parameters, possibly related to the 
activity of the disease (7).
As expected, the volume of distribution of 123I-AIgG 
decreased with higher levels of IgG. similarly to the 
relationship seen in patients with SLE. The pharmaco­
kinetic parameter halflife is derived from Vss and 
clearance (the second, terminal halllife correlating with 
the quotient Vss/clearance) (9). Accordingly, as Vss 
decreased and clearance remained unchanged, the second  
halflife also decreased after IVIG treatment. In contrast, 
in the patients with SLE, the expected second halflife 
shows no change with higher concentrations of IgG, as 
both Vss and clearance are decreased proportionally at 
these higher IgG concentrations (Tl ~  Vss/clearance).
In physiological terms, the decreased Vss of l 23I-AIgG 
after IVIG suggests that IgG impairs the binding o f 12 31 - 
A IgG to Fc receptors, by occupying available Fc 
receptors on Kupffer cells (10). However, the lack of an 
effect of IVIG on clearance of 1231- A IgG seems to 
indicate that endocytosis (as opposed to binding) of 
immune complexes is not influenced by plasma IgG. This 
is in accordance with in vitro studies in which the binding 
of affinity cross-linked IgG oligomers (used as model 
immune complexes) to Fc receptors was investigated. 
Monomeric IgG retarded the rate of association of these 
IgG oligomers with Fc receptors (11) but did not affect 
endocytosis ( 12 ).
It has been shown that IVIG prolongs the clearance of 
E -Ig G  by the spleen (3). Splenic Fc receptor blockade
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Figure 2. C learance (A), Vss (B), first (C) and  second (D) halflife in patients with hypogam m aglobulinem ia, before and  after 
IVIG. Asterisk: p < 0 0 5 .
100
Figure 3. Sucrose density gradient u ltra ­
centrifugation profile of 123I-AIgG in p lasm a at 
different time points after injection in a patient 
with hypogam m aglobu linem ia  after trea tm ent 
with IVIG. The da ta  are presented as percent of 
the radioactivity  in plasm a 3 min after injection 
l 23I-AIgG.
°/ c
50 -
10 -
1
3
AIgG 36-80 
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probably explains the therapeutic efficacy of IVIG in 
immune thrombocytopenic purpura (13), where the 
immune complex is a particle, similarly to E - lg G .  IVIG 
has also been administered therapeutically in patients 
with SLE, but results so far have been equivocal (14-16). 
The results presented here certainly offer no experimental 
evidence that IVIG has an effect on the clearance of 
soluble immune complexes by Fc receptor mediated
mechanisms in vivo. Theoretically, if the manifestations of
« / '
SLE are caused by deposition of soluble immune 
complexes in vessel walls and glomeruli, as a consequence  
of impaired Fc receptor function (1), IVIG induced Fc 
receptor blockade should not be expected to exert a 
beneficial effect in this disease. However, IVIG may have 
other immune modulatory effects, that may be of 
therapeutic use in patients with SLE. These include the 
proposed anti-idiotypic antibodies contained in the 
preparation (17), or its effects on autoantibody  
production (18. 19).
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